Over the last couple of years, one of the best pharma stocks to own has been Eli Lilly ( LLY 14.56%). But now, an investment ...

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

A daily weight loss pill being tested by Eli Lilly could work as well as its GLP-1 injection counterparts like Ozempic, ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

Eli Lilly GLP-1 pill orforglipron could revolutionize the weight loss world by the end of 2025 after promising Phase 3 trial ...

Shares of Eli Lilly jumped 16% Thursday morning after the pharmaceutical company released clinical trial results for its oral ...

A daily pill from drugmaker Eli Lilly has shown safety results comparable to the leading injectable GLP-1 drugs Mounjaro and ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The India launch of Eli Lilly's popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its ...

The company says its new drug in pill form is as safe and effective as Ozempic and other popular injectables for weight loss ...